Vimarsana
Biggest News Aggregation in the World

Page 10 - Ann Intern News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ann Intern. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ann Intern Today - Breaking & Trending Today

More States Providing Outpatient Hemodialysis for Undocumented Immigrants - Vimarsana News

More States Providing Outpatient Hemodialysis for Undocumented Immigrants

To provide equitable care, more states in the US are offering coverage for outpatient hemodialysis for undocumented immigrants.

Research on Cardiovascular Health and Longevity Focuses on AHA Life's Essential 8 (LE8) Components - Vimarsana News

Research on Cardiovascular Health and Longevity Focuses on AHA Life's Essential 8 (LE8) Components

Researchers who studied the impact of adherence to key health metrics on longevity have published findings that reinforce the value of lifestyle behaviors and health factors. The study, “Cardiovascular Health and Life Expectancy Among Adults in the United States,” was published April 10 in the American Heart Association (AHA) journal Circulation.

Study: Insulin Shelf Life Could Be 4 Times Longer than Previously Reported - Vimarsana News

Study: Insulin Shelf Life Could Be 4 Times Longer than Previously Reported

A new pilot study assessing the shelf life of insulin when stored at room temperature during the summer in India suggests most insulins maintained 95% potency or greater at 4 months relative to refrigerated insulin.

Parathyroidectomy May Not Preserve Kidney Function in Primary Hyperparathyroidism - Vimarsana News

Parathyroidectomy May Not Preserve Kidney Function in Primary Hyperparathyroidism

Leveraging data from more than 40,000 Veterans with primary hyperparathyroidism, a new NIA-funded study details the impact of parathyroidectomy on long-term kidney function among these patients.

POXEL SA: Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology - Vimarsana News

POXEL SA: Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology

PXL065 Phase 2 trial for the treatment of NASH met its primary efficacy endpoint for liver fat content reduction at 36-weeks for all doses. Fibrosis improvement by 1 stage without worsening